UPLOAD Filing
Merck & Co., Inc.
Date: April 28, 2025 · CIK: 0000310158 · Accession: 0000000000-25-004462
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Merck & Co., Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 1-06571 Dear Caroline Litchfield:
April 28, 2025
Caroline Litchfield Executive Vice President and Chief Financial Officer Merck & Co., Inc. 134 East Lincoln Ave. Rahway, NJ 07065
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 28, 2025 Caroline Litchfield Executive Vice President and Chief Financial Officer Merck & Co., Inc. 134 East Lincoln Ave. Rahway, NJ 07065 Re: Merck & Co., Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 1-06571 Dear Caroline Litchfield: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>